Search results

647 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

In development [GID-TA10541] Expected publication date: 24 February 2021

Type

Technology appraisal guidance

Status

In development
Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

In development [GID-TA10606] Expected publication date: 08 June 2022

Type

Technology appraisal guidance

Status

In development
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]

In development [GID-TA10630] Expected publication date: 23 March 2022

Type

Technology appraisal guidance

Status

In development
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

In development [GID-TA10451] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

In development [GID-TA10560] Expected publication date: 03 February 2021

Type

Technology appraisal guidance

Status

In development
Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: 03 February 2021

Type

Technology appraisal guidance

Status

In development
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID1313]

In development [GID-TA10312] Expected publication date: 24 February 2021

Type

Technology appraisal guidance

Status

In development
Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]

In development [GID-TA10639] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mental health community settings

In development [GID-SGWAVE0702] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Inpatient mental health settings

In development [GID-SGWAVE0701] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Community nursing care settings

In development [GID-SGWAVE0700] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Management and organisational approaches to safe staffing

In development [GID-SGWAVE0761] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Accident and emergency departments

In development [GID-SGWAVE0762] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

Type

NICE guideline

Status

In development
Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

Type

NICE guideline

Status

In development
Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

Type

NICE guideline

Status

In development
Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

Type

NICE guideline

Status

In development
Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

Type

NICE guideline

Status

In development
Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

Type

NICE guideline

Status

In development
Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

Type

NICE guideline

Status

In development
Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

Type

NICE guideline

Status

In development
Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Implantable Vagus Nerve Stimulator in Heart Failure

In development [GID-IP1145] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Obesity - phentermine (with topiramate) [ID543]

In development [GID-TAG439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]

In development [GID-TAG372] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

In development [GID-TAG423] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer - intensity modulated radiotherapy [ID17]

In development [GID-TAG396] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Colon cancer (adjuvant) - irinotecan [ID379]

In development [GID-TAG380] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

In development [GID-TAG330] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer (hormone refractory) - atrasentan [ID390]

In development [GID-TAG379] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

In development [GID-TAG300] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development